Patents by Inventor Anna Vulpetti

Anna Vulpetti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250115572
    Abstract: Provided herein are compounds of formula (I) and pharmaceutical compositions thereof useful for treating diseases or disorders mediated by the complement factor B. (I).
    Type: Application
    Filed: January 20, 2023
    Publication date: April 10, 2025
    Inventors: Christopher M. ADAMS, Lara C. CZABANIUK, Stefanie FLOHR, François GESSIER, Michael Christoph HEDIGER, Konstanze HURTH, Nancy LABBE-GIGUERE, Fabio LIMA, Tajesh PATEL, Oliver SIMIC, Martin SENDZIK, Angela VITREY, Anna VULPETTI
  • Publication number: 20250011333
    Abstract: Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.
    Type: Application
    Filed: December 22, 2023
    Publication date: January 9, 2025
    Inventors: Gabriella TRAQUANDI, Maria Gabriella Brasca, Roberto D'Alessio, Paolo Polucci, Fulvia Roletto, Anna Vulpetti, Palolo Pevarello, Achille Panzeri, Francesca Quartieri, Ron Ferguson, Paola Vianello, Daniele Fancelli
  • Publication number: 20240216513
    Abstract: Described herein are fatty acid-bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target proteins.
    Type: Application
    Filed: March 10, 2022
    Publication date: July 4, 2024
    Inventors: Claire Adcock, Valerie Broennimann, Jiashun Cheng, Rohit Kumar Duvadie, Tanzina Fazal, Jinhai Gao, Fengfeng Guo, Robert Martin Grotzfeld, Christina Hebach, Gregory John Hollingworth, Darryl Brynley Jones, Alexei Karpov, Jialiang Li, Julien Lorber, Chester A. Metcalf, III, Walter Michael, Mark Gabriel Palermo, Scott Vaughan Plummer, James Harold Roache, Martin Sendzik, Ranny Mathew Thomas, Aimee Richardson Usera, Anna Vulpetti, Frederic Zecri, Liang Zhao, Thomas Zoller
  • Publication number: 20240158399
    Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Application
    Filed: February 15, 2023
    Publication date: May 16, 2024
    Inventors: Luca ARISTA, Christina HEBACH, Gregory John HOLLINGWORTH, Philipp HOLZER, Patricia IMBACH-WEESE, Julien LORBER, Rainer MACHAUER, Niko SCHMIEDEBERG, Anna VULPETTI, Thomas ZOLLER
  • Publication number: 20230398117
    Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Application
    Filed: December 1, 2022
    Publication date: December 14, 2023
    Inventors: Luca ARISTA, Christina HEBACH, Gregory John HOLLINGWORTH, Philipp HOLZER, Patricia IMBACH-WEESE, Rainer MACHAUER, Niko SCHMIEDEBERG, Anna VULPETTI, Thomas ZOLLER
  • Publication number: 20230312483
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Application
    Filed: May 1, 2023
    Publication date: October 5, 2023
    Inventors: Daniela ANGST, François GESSIER, Anna VULPETTI
  • Patent number: 11673868
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: June 13, 2023
    Assignee: Novartis AG
    Inventors: Daniela Angst, François Gessier, Anna Vulpetti
  • Patent number: 11613543
    Abstract: The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: March 28, 2023
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Christina Hebach, Gregory John Hollingworth, Philipp Holzer, Patricia Imbach-Weese, Julien Lorber, Rainer Machauer, Niko Schmiedeberg, Anna Vulpetti, Thomas Zoller
  • Patent number: 11541056
    Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: January 3, 2023
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Christina Hebach, Gregory John Hollingworth, Philipp Holzer, Patricia Imbach-Weese, Rainer Machauer, Niko Schmiedeberg, Anna Vulpetti, Thomas Zoller
  • Publication number: 20220387602
    Abstract: Described herein are bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target proteins.
    Type: Application
    Filed: September 14, 2020
    Publication date: December 8, 2022
    Inventors: Luca ARISTA, Valerie BROENNIMANN, Pier Luca D'ALESSANDRO, Lionel DOUMAMPOUOM-METOUL, Marie-Line GOUDE, Christina HEBACH, Gregory John HOLLINGWORTH, Ingrid Karen Jennifer JEULIN, Louise Clare KIRMAN, Julien LORBER, Fupeng MA, Anna VULPETTI, Ken YAMADA, Thomas ZOLLER
  • Publication number: 20220363671
    Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.
    Type: Application
    Filed: September 16, 2020
    Publication date: November 17, 2022
    Inventors: Jake AXFORD, Rohan Eric John BECKWITH, Simone BONAZZI, Nicole BUSCHMANN, Artiom CERNIJENKO, Janetta DEWHURST, Aleem FAZAL, Matthew James HESSE, Lauren HOLDER, Viktor HORNAK, Hidetomo IMASE, Rama JAIN, Xianming JIN, John Ryan KERRIGAN, Julie LACHAL, Fupeng MA, Hasnain Ahmed MALIK, James R. MANNING, Daniel MCKAY, Robert Joseph MOREAU, Pierre NIMSGERN, Gary O'BRIEN, Anna VULPETTI, Ken YAMADA, Junping ZHAO
  • Publication number: 20220315578
    Abstract: The disclosure provides BRD9 bifunctional compounds of Formula (A), (BF-I), (BF-II), (BF-III), (BF-IIIa), (BF-IIIb), (BF-IV), (BF-IVa), (BF-IVb), (BF-I?), (BF-II?), (BF-III?), (BF-IV?), or (BF-V?), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, to their preparation, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases and disorders mediated by a bromodomain-containing protein, such as bromodomain-containing protein 9 (BRD9).
    Type: Application
    Filed: September 14, 2020
    Publication date: October 6, 2022
    Inventors: Xin CHEN, Marie-Line GOUDE, Edmund Martin HARRINGTON, Gregory John HOLLINGWORTH, Julien LORBER, Martin SENDZIK, Anna VULPETTI, Thomas ZOLLER
  • Publication number: 20220041561
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammartory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancer e.g. of hematopoietic origin or solid tumors.
    Type: Application
    Filed: October 22, 2021
    Publication date: February 10, 2022
    Inventors: Daniela ANGST, François GESSIER, Anna VULPETTI
  • Patent number: 11180460
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: November 23, 2021
    Assignee: Novartis AG
    Inventors: Daniela Angst, Francois Gessier, Anna Vulpetti
  • Publication number: 20210300935
    Abstract: Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.
    Type: Application
    Filed: October 30, 2020
    Publication date: September 30, 2021
    Inventors: Gabriella TRAQUANDI, Maria Gabriella BRASCA, Roberto D'ALESSIO, Paolo POLUCCI, Fulvia ROLETTO, Anna VULPETTI, Paolo PEVARELLO, Achille PANZERI, Francesca QUARTIERI, Ron FERGUSON, Paola VIANELLO, Daniele FANCELLI
  • Publication number: 20210251996
    Abstract: The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Application
    Filed: March 25, 2019
    Publication date: August 19, 2021
    Inventors: Luca Arista, Christina Hebach, Gregory John Hollingworth, Philipp Holzer, Patricia Imbach-Weese, Rainer Machauer, Niko Schmiedeberg, Anna Vulpetti, Thomas Zoller
  • Publication number: 20210002285
    Abstract: The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 7, 2021
    Inventors: Luca Arista, Christina Hebach, Gregory John Hollingworth, Philipp Holzer, Patricia Imbach-Weese, Julien Lorber, Rainer Machauer, Niko Schmiedeberg, Anna Vulpetti, Thomas Zoller
  • Publication number: 20200010426
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 9, 2020
    Inventors: Daniela Angst, Francois Gessier, Anna Vulpetti
  • Patent number: 10457647
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: October 29, 2019
    Assignee: Novartis AG
    Inventors: Daniela Angst, Francois Gessier, Anna Vulpetti
  • Publication number: 20190194214
    Abstract: Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.
    Type: Application
    Filed: March 4, 2019
    Publication date: June 27, 2019
    Inventors: Gabriella TRAQUANDI, Maria Gabriella BRASCA, Roberto D'ALESSIO, Paolo POLUCCI, Fulvia ROLETTO, Anna VULPETTI, Paolo PEVARELLO, Achille PANZERI, Francesca QUARTIERI, Ron FERGUSON, Paola VIANELLO, Daniele FANCELLI